Aligos Therapeutics - ALGS Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aligos Therapeutics in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALGS shares.
View ALGS analyst ratings or view top-rated stocks.

4 brokers have issued 1-year price targets for Aligos Therapeutics' shares. Their ALGS share price forecasts range from $2.00 to $7.00. On average, they expect the company's share price to reach $4.00 in the next year. This suggests a possible upside of 203.0% from the stock's current price.
View analysts price targets for ALGS or view top-rated stocks among Wall Street analysts.

Aligos Therapeutics' stock was trading at $0.9529 at the beginning of the year. Since then, ALGS shares have increased by 38.5% and is now trading at $1.32.
View the best growth stocks for 2023 here.

Aligos Therapeutics saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 853,900 shares, an increase of 16.2% from the February 13th total of 735,100 shares. Based on an average trading volume of 402,600 shares, the days-to-cover ratio is presently 2.1 days. Approximately 2.9% of the shares of the stock are sold short.
View Aligos Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our ALGS earnings forecast.

Aligos Therapeutics, Inc. (NASDAQ:ALGS) issued its quarterly earnings data on Wednesday, November, 3rd. The company reported ($0.78) earnings per share for the quarter, topping analysts' consensus estimates of ($0.81) by $0.03. The business had revenue of $1.54 million for the quarter. Aligos Therapeutics had a negative net margin of 690.63% and a negative trailing twelve-month return on equity of 74.49%.

(ALGS) raised $150 million in an initial public offering on Friday, October 16th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P.Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO and Cantor was co-manager.

Aligos Therapeutics trades on the NASDAQ under the ticker symbol "ALGS."

Aligos Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Tang Capital Management LLC (6.58%), Point72 Asset Management L.P. (2.12%), Renaissance Technologies LLC (1.24%), Millennium Management LLC (0.87%), New York Life Investment Management LLC (0.62%) and Geode Capital Management LLC (0.47%). Insiders that own company stock include Thomas Woiwode and Vivo Capital Fund Viii, LP.
View institutional ownership trends.

Shares of ALGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALGS stock can currently be purchased for approximately $1.32.

Aligos Therapeutics (NASDAQ:ALGS) has a market capitalization of $56.68 million and generates $13.91 million in revenue each year. The company earns $-96,050,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis.

The official website for the company is www.aligos.com. The company can be reached via phone at 800-466-6059 or via email at cdavis@lifesciadvisors.com.